Abstract:Abstract Triple Negative Breast Cancer (TNBC) affects approximately 15-20% of BC patients, yet accounts for a disproportionately higher rate of BC morbidity and mortality, in part due to lack of targeted therapies. We have shown that estrogen receptor beta (ERβ) is expressed in approximately 20% of TN breast tumors and that ligand-mediated activation of ERβ with estradiol (E2) or ERβ-selective agonists decreases tumor cell proliferation, invasion and migration in vitro and in vivo. Therefore, we aimed to elucidate the mechanisms by which ERβ elicits its anti-cancer effects in TNBC. RNAseq analysis of ERβ-expressing MDA-MB-231 cells demonstrated that ERβ significantly downregulates NFκB signaling in the presence of E2. ChIPseq for ERβ in these cells revealed that ERβ primarily associated with estrogen response elements, but 12% of all ERβ binding sites were located at NFκB consensus motifs. Using an NFκB reporter construct and qPCR, ERβ was shown to block TNFα-mediated induction of NFκB signaling and NFκB target gene expression. RNAseq analysis of MDA-MB-231-ERβ cells treated with TNFα or E2+TNFα revealed substantial global inhibition of TNFα regulated genes in the presence of E2. ChIPseq for NFκB demonstrated that ERβ significantly alters NFκB’s cistrome whereby it can both diminish NFκB binding and redistribute NFκB throughout the genome. ChIPseq also demonstrated that ligand-mediated activation of ERβ significantly diminished an activating histone mark (H3K27Ac) at many of these NFκB target genes while enhancing a repressive mark (H3K27Me3). The addition of H3K27Me3 at these loci was shown to occur through the recruitment of the histone methyltransferase, EZH2. Drug-mediated blockade of EZH2 activity reversed suppression of NFκB target gene expression by ERβ. Knockdown of NFκB or Mutation of ERβ’s DNA binding domain rendered ERβ incapable of associating with DNA, recruiting EZH2, methylating NFκB target gene loci, repressing NFκB target gene expression and inhibiting proliferation. Interestingly, ERβ was shown to elicit more potent anti-cancer effects in TNBC cells expression a constitutively active form of NFκB. These finding suggest that a primary mechanism by which ERβ functions as a tumor suppressor is through inhibition of NFκB pathway activity. Our studies have also revealed that ERβ functions as a molecular switch for EZH2 and repurposes it for tumor suppressive activities, as EZH2 has previously been reported to enrich NFκB signaling in TNBC. These findings could address the paradox that high EZH2 expression is associated with worse TNBC patient outcomes, while high H3K27Me3 expression is associated with improved patient outcomes. Currently, a Mayo Clinic Breast Cancer SPORE prospective phase II clinical trial is underway to investigate the efficacy of estradiol for the treatment of metastatic ERβ+TNBC and to further evaluate the cross-talk between ERβ, EZH2 and NFκB signaling.

Estrogen-Induced Interaction Between Klf5 And Estrogen Receptor (Er) Suppresses The Function Of Er In Er-Positive Breast Cancer Cells

Overexpression of ERα Inhibits Proliferation and Invasion of MKN28 Gastric Cancer Cells by Suppressing Β-Catenin

Oestrogen Causes Degradation of KLF5 by Inducing the E3 Ubiquitin Ligase EFP in ER-positive Breast Cancer Cells

KLF6 inhibits estrogen receptor-mediated cell growth in breast cancer via a c-Src-mediated pathway

Keratin 18 Attenuates Estrogen Receptor Α-Mediated Signaling by Sequestering LRP16 in Cytoplasm

Toll-Like Receptor 9 Agonist Inhibits Er Alpha-Mediated Transactivation by Activating Nf-Kappa B in Breast Cancer Cell Lines

Estrogen Receptor Β1 Expression Patterns Have Different Effects on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors' Treatment Response in Epidermal Growth Factor Receptor Mutant Lung Adenocarcinoma.

Stable Knockdown of Estrogen Receptor Alpha by Vector-Based Rna Interference Suppresses Proliferation and Enhances Apoptosis in Breast Cancer Cells

Estrogen Receptor Α Mediates Proliferation of Breast Cancer MCF–7 Cells Via a P21/pcna/e2f1‐dependent Pathway

ERα upregulates the expression of long non-coding RNA LINC00472 which suppresses the phosphorylation of NF-κB in breast cancer

SUN-LB135 Estrogen Receptor Beta Inhibits NFkB Signaling to Inhibit Triple Negative Breast Cancer

KRAB-containing Zinc Finger Protein ZNF496 Inhibits Breast Cancer Cell Proliferation by Selectively Repressing ERα Activity.

Estrogen receptor α mediates proliferation of breast cancer MCF-7 cells via a p21/PCNA/E2F1-dependent pathway.

KLF5 Promotes Breast Cell Survival Partially Through Fibroblast Growth Factor-Binding Protein 1-Perk-mediated Dual Specificity MKP-1 Protein Phosphorylation and Stabilization.

Novel Insight into KLF4 Proteolytic Regulation in Estrogen Receptor Signaling and Breast Carcinogenesis

FOXK2 Transcription Factor Suppresses ERα-positive Breast Cancer Cell Growth Through Down-Regulating the Stability of ERα Via Mechanism Involving BRCA1/BARD1.

Krupple-Like Factor 5 Promotes Breast Cancer Proliferation Through Activating Fibroblast Growth Factor-Binding Protein Transcription

Krüppel-like Factor 5 Promotes Breast Cell Proliferation Partially Through Upregulating the Transcription of Fibroblast Growth Factor Binding Protein 1.

KLF15 Suppresses Tumor Growth and Metastasis in Triple-Negative Breast Cancer by Downregulating CCL2 and CCL7.

Abstract 1284: Estrogen Receptor Alpha Transcriptionally Regulates P53 in MCF7 Human Breast Cancer Cells

Estrogen Receptor Β2 Negatively Regulates the Transactivation of Estrogen Receptor Α in Human Breast Cancer Cells